Phase I psilocybin safety trial

This open-label, phase I trial (n=14) conducted by The Newly Institute in Canada aims to assess the safety of psilocybin (25mg) when administered to healthy participants enrolled in a psychedelic-assisted therapy training program. The study spanned from August 2021 to August 2022 and was retrospectively registered.

The primary focus was on documenting psilocybin safety in healthy participants aged 18-65, primarily licensed healthcare professionals. Participants enrolled in the ATMA 8-week psychedelic-assisted therapy training program received 25 mg of oral psilocybin, and the study involved evaluating physiological parameters such as blood pressure, heart rate, temperature, and ECG. Safety was monitored at baseline, during the psilocybin session, and at 8 weeks post-session, with adverse events recorded. Secondary outcomes included assessing mood and mystical experiences.

While the study has been completed, the results have yet to be published. ATMA Journey Centers Inc. funded the trial, and Jennifer Bennett is its main contact.

Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

ATMA Journey Centers
ATMA Journey Centers was Canada’s first private therapy company to conduct legal psychedelic-assisted therapy using psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.